A vial is the one part of a research-peptide purchase that looks unambiguously professional. The glass is right, the stopper is right, the crimp is right, and the flip-off cap comes off with the same small snap it does on a pharmacy shelf.
All of that is real, and almost none of it is evidence. The rules that make a pharmaceutical container mean something attach to the product inside it, not to the glass. This page sets out what the container actually is, what the applicable standards cover, and what a compliant label carries — so that the parts a buyer can verify are separated from the parts they cannot.
How brands appear on this site is set out on our disclosure page.
The glass
FDA's guidance Container Closure Systems for Packaging Human Drugs and Biologics (July 1999) states the position directly: cartridges, syringes, vials and ampoules "are usually composed of Type I or II glass, or polypropylene", and stoppers and septa in those containers "are typically composed of elastomeric materials."
The three USP glass classes differ in chemical resistance:
| Class | What it is | Typical use |
|---|---|---|
| Type I | Borosilicate | Parenterals, including anything sensitive to alkali extraction |
| Type II | Treated soda-lime — surface de-alkalised | Some aqueous parenterals |
| Type III | Untreated soda-lime | Generally non-parenteral |
The guidance quotes the USP General Notices requirement that certain products be preserved "in single-dose or in multiple-dose containers, preferably of Type I glass, protected from light." Type I borosilicate is the parenteral default, and it is what most injectable-format vials — including research-market ones — are made from.
That is a specification a supplier can meet by buying the right glass. It says nothing about the contents.
The closure system, in three parts
The parts are routinely conflated, and they do different jobs.
The stopper is the closure. It is an elastomeric component, usually bromobutyl or chlorobutyl rubber, and it is what the needle pierces and what re-seals behind it. USP <381> Elastomeric Closures for Injections is the chapter covering it, and it is listed in the FDA guidance among the chapters applicable to packaging components.
The seal is the aluminium crimp ring that holds the stopper mechanically against the glass. Once crimped, the stopper cannot be lifted without destroying the seal.
The flip-off button is a plastic disc covering the centre of the crimp. Its only job is keeping the septum clean until first use. Removing it does not open anything — a point worth making because the snap it makes reads like opening a container, and the container is still closed.
For lyophilized products there is a fourth detail: the stopper used in a freeze-drying cycle is slotted or two-legged, and sits partially inserted through the drying phase so water vapour can escape, before being pushed fully home inside the dryer and crimped afterwards. The stopper's shape is a process artefact.
Fill volume, and why a vial looks empty
A 10 mg lyophilized peptide arrives in a vial that appears almost empty, and this is normal.
Lyophilization requires the fill to sit as a shallow layer relative to the vial's cross-section so the cake dries evenly, and requires substantial headspace for vapour transport during drying. A vial filled to the shoulder would not lyophilize properly. The visible cake is small because the process demands it, not because the vial is short-measured.
The corollary is that the vial size carries no information about the contents. The same 10 mg can appear in a 2 mL or a 10 mL vial depending on the filler's equipment, and the cake's apparent size varies with how fast it was frozen.
What the regulations actually cover
This is the part that decides how much a vial is worth as evidence.
21 CFR 211.94 — drug product containers and closures:
Drug product containers and closures shall not be reactive, additive, or absorptive so as to alter the safety, identity, strength, quality, or purity of the drug beyond the official or established requirements.
It also requires the system to protect against foreseeable external factors in storage and use, and that depyrogenation processes be validated.
21 CFR 211.84 requires that each lot of containers and closures be withheld from use until sampled, tested or examined and released by the quality control unit. 21 CFR 211.82 requires visual examination on receipt — for labelling, container damage, broken seals and contamination — and quarantine until tested. 21 CFR 211.80 requires written procedures for the whole chain and a distinctive lot code on every incoming shipment.
The USP chapters the FDA guidance lists as applicable to packaging components run to ten: <1> Injections, <51> Antimicrobial Preservatives — Effectiveness, <61> Microbial Limit Tests, <71> Sterility Tests, <87> and <88> Biological Reactivity Tests in vitro and in vivo, <161> Transfusion and Infusion Assemblies, <381> Elastomeric Closures for Injections, <601>, and <661> Containers — Plastics.
Every one of those obligations attaches to a manufacturer producing a drug product. None of them attaches to a container because of what it is made of. A supplier selling research-use-only contents is outside that framework entirely — and can, entirely truthfully, be using correct Type I vials with correct <381>-compliant stoppers the whole time.
The hardware is genuine. It is simply not the thing that was being certified.
What a compliant injectable label carries
The clearest way to see what a label is supposed to do is to read one that has to. FORZINITY's 2025 label, read on 2026-09-11, states:
| Element | What it says |
|---|---|
| Established name | Elamipretide (elamipretide hydrochloride) injection |
| Strength | 280 mg/3.5 mL (80 mg/mL) |
| Presentation | Single-patient-use vials, four per carton |
| NDC | 72507-800-04 |
| Description | Sterile, clear, colourless to yellow aqueous solution |
| Storage | 2°C to 8°C (36°F to 46°F); do not freeze |
| In-use | Discard vials 8 days after first opening |
| Inspection | Visually inspect for particulate matter and cloudiness; do not use if cloudy or particulate matter is present |
Two things in that table are worth pulling out.
The strength convention. Amount per total volume comes first, concentration second, in parentheses. The order is deliberate: a vial marked 80 mg/mL holds 280 mg because it contains 3.5 mL, and reading the concentration as the contents understates the vial by a factor of 3.5. This is one of the most common misreadings of any injectable label.
For a lyophilized product there is no volume until someone adds diluent, so the label can only state a mass. The concentration is created by the person reconstituting it — which is exactly why our reconstitution page exists and why the same 5 mg vial can yield 2.5 mg/mL or 5 mg/mL depending on nothing but the diluent volume.
The in-use limit. Eight days, and that number is only possible because the product contains benzyl alcohol as a preservative. An unpreserved solution has no such window. Our bacteriostatic water page covers the difference between preserved and unpreserved diluents and what each does to an in-use period — the single most consequential storage question after reconstitution.
What a buyer can actually check
- The glass and closure are checkable by eye — clear borosilicate, an intact elastomeric stopper, an undamaged aluminium crimp, a flip-off button still seated.
- The label is checkable against the list above — established name, mass, lot, expiry, storage. Missing elements are informative; present ones prove only that they were printed. The research-use caution is checkable in the same spirit and rarely is: two regulations produce such a statement, they require different sentences, and the wording most vials carry matches neither.
- The lot number is checkable for consistency — against the certificate of analysis, if one was supplied for that specific lot rather than for the compound generally. Our page on reading a certificate of analysis covers what that document does and does not establish.
- The cake is checkable for the obvious — a collapsed, melted or oily-looking cake, or one that has shifted as though it was liquid in transit, indicates a temperature excursion.
- What is not checkable by the buyer at all is whether the container lot was released by a quality control unit, whether depyrogenation was validated, or whether the fill was aseptic. Those are the 211.84 and 211.94 obligations, and outside the drug framework nobody owes them.
What this page does not do
It does not tell anyone what to buy, and it does not treat correct hardware as a quality signal. The reason to know what a vial is made of is to stop the container from carrying the weight of a claim about its contents — which, in a market where the packaging is frequently the most professional-looking element of a purchase, is the specific mistake worth avoiding.
Related on this site
Our storage page covers temperature and light, our reconstitution page covers the arithmetic that turns a mass into a concentration, and our syringe page covers what the unit markings mean and where dead space goes. Our certificate of analysis page covers the document that is supposed to say what is in the vial.
Sources and dates
Opened 2026-09-11: FDA's guidance Container Closure Systems for Packaging Human Drugs and Biologics (July 1999), from which the glass-type and elastomeric-closure statements, the USP General Notices quotation and the list of applicable USP general chapters are taken verbatim; the eCFR API for 21 CFR part 211 subpart E, from which §§ 211.80, 211.82, 211.84 and 211.94 are quoted; and the DailyMed structured product label for FORZINITY (setid 146bf34c-76f2-48db-ac07-fb29cce2cd75, SPL version 10, published 12 December 2025), from which the strength, presentation, NDC, storage, in-use limit and inspection instruction are taken. The lyophilization stopper and fill-depth descriptions are general process facts and are stated as such rather than sourced to a single document. Corrections go to the contact page.